Business Context and Reporting Period
Company: Ascendis Pharma A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Business Overview: Ascendis Pharma is a clinical-stage biopharmaceutical company developing long-acting prodrug therapies using its proprietary TransCon technology. The company has no approved products and generates revenue primarily through collaboration agreements, licensing fees, and research services. Its lead product candidate is TransCon human growth hormone (TransCon hGH) for the treatment of growth hormone deficiency (GHD).
Key Financial Metrics
| Metric (EUR '000) | 2015 | 2014 | 2013 |
|---|---|---|---|
| Revenue | 8,118 | 13,983 | 20,408 |
| Research & Development Costs | (40,528) | (19,698) | (12,713) |
| General & Administrative Expenses | (9,415) | (6,274) | (2,416) |
| Operating Loss | (41,825) | (11,989) | 5,279 |
| Net Loss | (32,922) | (9,658) | 4,079 |
| Cash and Cash Equivalents (Year End) | 119,649 | 50,167 | 19,430 |
| Total Equity | 120,329 | 45,810 | 6,301 |
| Outstanding Ordinary Shares | 25,128,242 | 16,935,780 | 10,801,948 |
Note: Financial statements are prepared in accordance with IFRS. The company reported a significant net finance income of €11.0 million in 2015, primarily due to favorable exchange rate fluctuations between the USD and EUR following its IPO.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 42% to €8.1 million in 2015 from €14.0 million in 2014. This was driven by the termination of the collaboration with United Therapeutics in mid-2014 and reduced service revenue from Sanofi and Genentech.
- Increased R&D Spend: R&D costs more than doubled to €40.5 million (up 106% from 2014). The increase was primarily due to external costs for the Phase 2 pediatric TransCon hGH study, manufacturing costs, and preparation for the Phase 3 study.
- Liquidity Expansion: Cash and cash equivalents increased by €69.5 million to €119.6 million. This was fueled by net proceeds of approximately €101.4 million from the February 2015 Initial Public Offering (IPO) and €4.3 million from warrant exercises.
- Net Loss Widening: The net loss widened to €32.9 million from €9.7 million in the prior year, reflecting the surge in operating expenses despite the one-time gain from currency fluctuations.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Progress: In July 2015, the company announced positive top-line results from a six-month Phase 2 study of TransCon hGH in pediatric patients. A pivotal Phase 3 study is planned to initiate in mid-2016.
- Liquidity Runway: Management believes existing cash reserves are sufficient to fund operations for at least 12 months from the date of the report (April 2016).
- Future Expenses: The company anticipates substantial increases in expenses as it advances clinical trials, expands its workforce, and incurs costs associated with being a public company.
Risks and Contingencies
- Internal Control Weaknesses: The company identified material weaknesses in its internal control over financial reporting as of December 31, 2015. These included a material error in R&D cost recognition and incomplete design of entity-level controls.
- Capital Requirements: As a clinical-stage company with no product sales, Ascendis requires substantial additional financing. Failure to secure capital could force delays or cessation of development programs.
- Regulatory Uncertainty: Success depends on regulatory approval of TransCon hGH, which relies on a Section 505(b)(2) pathway. There is no guarantee that a single Phase 3 trial will be sufficient for approval.
- Collaboration Dependence: Future revenue is heavily dependent on milestone payments and royalties from partners (Sanofi, Genentech), which are uncertain and subject to partner performance.
Key Facts for Investor Verification
- Phase 3 Timeline: Verify the initiation date of the pivotal Phase 3 study for TransCon hGH, currently targeted for mid-2016.
- Remediation of Internal Controls: Monitor the company's progress in remediating the identified material weaknesses in internal financial controls to ensure future reporting accuracy.
- Cash Burn Rate: Track quarterly cash consumption to confirm the 12-month liquidity runway remains valid given the high R&D spend.
- Collaboration Milestones: Review the status of development milestones with Sanofi and Genentech, as these represent potential future revenue streams.
- Regulatory Strategy: Confirm FDA and EMA feedback regarding the proposed single Phase 3 trial design and the 505(b)(2) regulatory pathway.